Sarah Mount: Pregnancy, Hypercoagulability, and Erythritol
Sarah Mount, Postdoctoral Researcher at Maastricht University, shared on LinkedIn:
”Pregnancy, Hypercoagulability, and Erythritol — A Conversation We Should Be Having
Pregnancy is not a neutral physiological state when it comes to clotting.
It is a well-established hypercoagulable condition, designed to protect against haemorrhage — but one that increases the risk of thrombosis.
That baseline risk is compounded by:
- Gestational diabetes
- Hypertensive disorders of pregnancy (including pre-eclampsia)
- Chronic hypertension
- Obesity and metabolic dysfunction
- Inherited thrombophilia’s ex. Factor V Leiden (often undiagnosed, as universal screening is not routine).
Placental function depends on stable microvascular blood flow. When thrombotic risk rises, placental complications — including abruption and infarction — can escalate rapidly.
Now consider emerging data on erythritol (E968).
A 2023 study published in Nature Medicine reported that higher circulating erythritol levels were associated with increased risk of major adverse cardiovascular events (MI, stroke, death) over three years in high-risk populations.
Experimental components of the study demonstrated enhanced platelet activation and thrombosis formation in vitro and in animal models.
A subsequent human intervention study showed that ingestion of erythritol-sweetened beverages can produce plasma levels associated with these pro-thrombotic effects.
Moreover, there are more recent studies examining erythritol and blood-brain barrier integrity, as well as cardiovascular event risks.
Importantly:
These studies show association and mechanistic plausibility — not proven causation.
Erythritol remains ‘generally recognised as safe’ under current regulatory frameworks. Pregnancy-specific outcome data are lacking.
But here is the clinical question:
In a population already in a hypercoagulable state — sometimes with additional metabolic, hypertensive, or genetic risk factors — does it seem unreasonable to at least discuss minimising exposure to compounds with emerging pro-thrombotic signals?
This is not alarmism. It is risk stratification.
At minimum, this appears to be a reasonable topic for informed discussion between pregnant patients and their obstetric providers.
And then there is labelling…”
Stay updated with Hemostasis Today.
-
Apr 10, 2026, 01:19Heghine Khachatryan: When Vascular Fragility Defines Risk – Rethinking Hemostasis in LDS
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH
-
Apr 9, 2026, 21:37Arun V J: The Nation Inside the Human Body and Blood Function
-
Apr 9, 2026, 21:36José Antonio García Erce: Fall of While Blood Donation And Apheresis Growth in Spain
-
Apr 9, 2026, 21:34Chokri Ben Lamine: High-Yield Clinical Insights on Carfilzomib-Induced aHUS
-
Apr 9, 2026, 21:29Satyam Arora: Improving Thalassaemia Care in India Through Ground-Level Data
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC